Skip to main content
. Author manuscript; available in PMC: 2023 Feb 5.
Published in final edited form as: Mol Cancer Res. 2022 Aug 5;20(8):1183–1192. doi: 10.1158/1541-7786.MCR-22-0111

Figure 2. PARP inhibition enhances cisplatin-mediated cytotoxicity in HeLa cells without increasing DNA damage.

Figure 2.

HeLa (A) and Caski (B) cells were treated with the PARP inhibitor BYK (10 μM), the chemotherapeutic drug cisplatin (CDDP; 2 μM), or both in combination as indicated. Cells were collected and stained with crystal violet at day 0, 2, 4, 6 and 8 (top panel). Cell survival was quantified for each of the time points by measuring absorbance at O.D. 595nm (bottom panel). Each point represents the mean ± SEM (n = 4; Fisher’s LSD test; * p < 0.05).